Evidence map›Paper›PMID 27437873›Full record

SynthesisOncotarget2016

A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.

Rafael Ríos-Tamayo, Carmen Belén Lupiañez, Daniele Campa, Thomas Hielscher, Niels Weinhold, Joaquin Martínez-López, Andrés Jerez, Stefano Landi, Krzysztof Jamroziak, Charles Dumontet and 18 more

Abstract readMeta-Analysis
In one paragraph

Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Rafael Ríos-TamayoGenomic Oncology Area, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Granada, Spain.
Carmen Belén LupiañezGenomic Oncology Area, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Granada, Spain.
Daniele CampaDepartment of Biology, University of Pisa, Pisa, Italy.
Thomas HielscherDivision of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Niels WeinholdMyeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Joaquin Martínez-LópezDepartment of Hematology, Hospital Universitario Doce de Octubre, Madrid, Spain.
Andrés JerezHematology and Medical Oncology Department, University Hospital Morales Meseguer, IMIB, Murcia, Spain.
Stefano LandiDepartment of Biology, University of Pisa, Pisa, Italy.
Krzysztof JamroziakMedical University of Lodz, Lodz, Poland.
Charles DumontetINSERM UMR 1052/CNRS 5286, Universite Claude Bernard Lyon I, Lyon, France.
Marzena WątekHematoloy Clinik, Holy Cross Cancer Center, Kielce, Poland.
Fabienne LesueurInstitute Curie, Paris, France.
Rui Manuel ReisLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
Herlander MarquesLife and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal.
Artur JurczyszynJagiellonian University Medical College, Department of Haematology, Kraków, Poland.
Ulla VogelNational Research Centre for the Working Environment, Copenhagen, Denmark.
Gabriele BudaUO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy.
Ramón García-SanzHaematology Department, University Hospital of Salamanca & IBSAL, Salamanca, Spain.
Enrico OrciuoloUO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy.
Mario PetriniUO Hematology, Department of Internal and Experimental Medicine, University of Pisa, Pisa, Italy.
Annette J VangstedDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.
Federica GemignaniDepartment of Biology, University of Pisa, Pisa, Italy.
Asta FörstiMolecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Hartmut GoldschmidtDepartment of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Kari HemminkiMolecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Federico CanzianINSERM UMR 1052/CNRS 5286, Universite Claude Bernard Lyon I, Lyon, France.
Manuel JuradoGenomic Oncology Area, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Granada, Spain.
Juan SainzGenomic Oncology Area, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetogenic single nucleotide polymorphisms (SNPs) have recently been associated with multiple myeloma (MM) risk but their impact on overall survival (OS) of MM patients has not been analysed yet. In order to investigate the impact of 58 GWAS-identified variants for type 2 diabetes (T2D) on OS of patients with MM, we analysed genotyping data of 936 MM patients collected by the International Multiple Myeloma rESEarch (IMMENSE) consortium and an independent set of 700 MM patients recruited by the University Clinic of Heidelberg. A meta-analysis of the cox regression results of the two sets showed that rs7501939 located in the HNF1B gene negatively impacted OS (HRRec= 1.44, 95% CI = 1.18-1.76, P = 0.0001). The meta-analysis also showed a noteworthy gender-specific association of the SLC30A8rs13266634 SNP with OS. The presence of each additional copy of the minor allele at rs13266634 was associated with poor OS in men whereas no association was seen in women (HRMen-Add = 1.32, 95% CI 1.13-1.54, P = 0.0003). In conclusion, these data suggest that the HNF1Brs7501939 SNP confers poor OS in patients with MM and that a SNP in SLC30A8 affect OS in men.

Indexed as

GenotypeSex FactorsDiabetes Mellitus, Type 2FemaleGene FrequencyGenetic Predisposition to DiseaseGenome-Wide Association StudyHepatocyte Nuclear Factor 1-betaHumansMaleMultiple MyelomaPolymorphism, Single NucleotideSurvival AnalysisZinc Transporter 8Hepatocyte Nuclear Factor 1-betaHNF1B protein, humanSLC30A8 protein, humanZinc Transporter 8diabetesgenetic variantsmultiple myelomasurvival

Identifiers

PMID27437873
PMCPMC5312293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.